Micafungine Hikma (Micafungin)

• Micafungin is an echinocandin antifungal that targets Candida species in serious infections.
• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves mucosal infection of the esophagus.
• Prophylaxis in hematopoietic stem cell transplant patients: prevents Candida infection during periods of neutropenia.

• Micafungin inhibits the enzyme β‑1,3‑D‑glucan synthase, blocking synthesis of β‑1,3‑D‑glucan, an essential structural component of the fungal cell wall. This disruption weakens the wall, leading to osmotic instability and cell death, while sparing human cells that lack this pathway.

Micafungin may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

• Fever or chills during infusion.
• Nausea or mild gastrointestinal discomfort.
• Headache or transient dizziness.
• Infusion‑related erythema or rash.
• Elevated liver enzymes (ALT, AST).
• Mild transient hypotension.

Serious or Rare Side Effects

• Severe hepatic dysfunction or hepatitis.
• Anaphylactic or severe allergic reactions.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Acute renal failure or significant creatinine rise.
• Severe hypotension requiring intervention.
• Eosinophilia with systemic symptoms.

• Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.
• Monitor liver function: obtain baseline and periodic LFTs during treatment.
• Assess renal function: adjust therapy if severe renal impairment is present.
• Check for hypersensitivity: discontinue if signs of allergic reaction appear.
• Use caution in patients with pre‑existing hepatic disease.
• Avoid concurrent use with strong CYP3A4 inducers without dose adjustment.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes; awareness helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Concomitant use with strong CYP3A4 inducers (e.g., rifampin) may markedly reduce micafungin exposure.
• Co‑administration with other echinocandins can increase risk of additive toxicity.
• Use with known hypersensitivity agents may precipitate severe allergic reactions.

Moderate Interactions (Monitor Closely)

• Azole antifungals may elevate liver enzymes; monitor hepatic function.
• Immunosuppressants such as cyclosporine may require level checks.
• Warfarin therapy may experience INR fluctuations; monitor coagulation.
• Concurrent nephrotoxic drugs could exacerbate renal impairment.
• Combination with other antifungals may increase overall toxicity profile.